{"id":137945,"date":"2026-03-28T04:36:33","date_gmt":"2026-03-28T07:36:33","guid":{"rendered":"https:\/\/ces.einnews.com\/article\/902258580"},"modified":"2026-03-28T04:36:33","modified_gmt":"2026-03-28T07:36:33","slug":"fda-loosens-regulatory-oversight-for-digital-health-innovation","status":"publish","type":"post","link":"https:\/\/new7.shop\/zerocostfreehost\/index.php\/2026\/03\/28\/fda-loosens-regulatory-oversight-for-digital-health-innovation\/","title":{"rendered":"FDA loosens regulatory oversight for digital health innovation"},"content":{"rendered":"<div class=\"article__below-title\">\n<div class=\" article__posted-date\">\n<p>March 27, 2026<\/p>\n<p>8 min read<\/p>\n<\/p><\/div>\n<div class=\"mobile-trust-box\">\n<div class=\"row\">\n<div class=\"col-12 col-md-6 offset-md-1 offset-xl-0 col-xl-12\">\n<div class=\"email-alert-button-wrapper d-none\" data-component=\"EmailTopicAlert\" data-module=\"Subspecialty Email Topic Alerts Top\" data-manage-email-link=\"\/footer\/account-information\/my-account\/email-subscriptions-and-alerts#emailAlerts\">\n<div class=\"email-alert-button d-none\" data-topic-button=\"not-subscribed\">\n<p> <span data-module-track-action=\"Email Alerts TOP_Click_Healio News Article\" data-module-track-label=\"Email Alerts TOP_Healio News Article\"> <i class=\"fas fa-plus-circle\"><\/i> Add topic to email alerts <\/span> <\/p>\n<div class=\"email-alert-inner collapse u4d5c8cd2d9164cf9a829bee5c0694d71\">\n<div class=\"email-alert-dialogue\">\n<p> Receive an email when new articles are posted on <span data-content=\"topic-title\"><\/span> <\/p>\n<div class=\"d-none\" data-sign-up-type=\"unknown\"> Please provide your email address to receive an email when new articles are posted on <span data-content=\"topic-title\"><\/span>. <\/div>\n<\/p><\/div>\n<p> &lt;button type=&quot;button&quot; class=&quot;btn btn-primary&quot; data-loading-text=&quot;Loading <i class='fa fa-spinner fa-spin'><\/i>&#8221; data-action=&#8221;subscribe&#8221;&gt; Subscribe <\/button> <\/div>\n<\/p><\/div>\n<div class=\"email-alert-button d-none\" data-topic-button=\"subscribed\">\n<p> <i class=\"fas fa-check-circle\"><\/i> <span>Added to email alerts<\/span> <\/p>\n<\/p><\/div>\n<div class=\"d-none\" data-topic-modal=\"failed\"> <strong>We were unable to process your request. Please try again later. If you continue to have this issue please contact <a href=\"mailto:customerservice@slackinc.com\">customerservice@slackinc.com<\/a>.<\/strong> <\/p>\n<p><button data-dismiss=\"modal\" class=\"btn btn-primary btn-lg btn-block\">Back to Healio<\/button><\/p>\n<\/div>\n<\/div><\/div>\n<\/p><\/div>\n<\/p><\/div>\n<\/p><\/div>\n<h2>Key takeaways:<\/h2>\n<ul>\n<li>One presentation at this year\u2019s vMed conference highlighted updated federal policies in the digital health space.<\/li>\n<li>The expert broke down the implications for providers, patients and businesses.<\/li>\n<\/ul>\n<p>LOS ANGELES \u2014 It is important for primary care providers to understand new federal regulations surrounding wearables, wellness and clinical decision support, especially because it will impact reimbursement, according to a speaker here.<\/p>\n<p> <b>Aubrey Shick<\/b>, a former official in the FDA\u2019s Digital Health Center of Excellence, offered a presentation on FDA\u2019s January 2026 updates, and how they \u201cchange the game\u201d for <a rel=\"noopener noreferrer\" href=\"https:\/\/www.healio.com\/news\/primary-care\/20251119\/wearable-technology-can-offer-insights-for-health-care-workers-and-engage-patients\" id=\"rId12\" target=\"_blank\">wearables<\/a>, clinical decision support and wellness at Cedars-Sinai\u2019s eighth annual iteration of its Virtual Medicine Conference, vMed.<\/p>\n<figure class=\"figure article__og-image\">       <img data-opt-id=758893364  fetchpriority=\"high\" decoding=\"async\" src=\"data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/ywAAAAAAQABAAACAUwAOw==\" fifu-lazy=\"1\" fifu-data-sizes=\"auto\" fifu-data-srcset=\"https:\/\/mlmjbqro95r8.i.optimole.com\/cb:bOxR.6a5\/w:auto\/h:auto\/q:mauto\/f:best\/https:\/\/i1.wp.com\/www.healio.com\/~\/media\/slack-news\/fm_im\/misc\/infographics\/2026\/03_march\/pc0326shick_graphic_01_web.jpg?w=800&ssl=1&w=75&resize=75&ssl=1 75w, https:\/\/mlmjbqro95r8.i.optimole.com\/cb:bOxR.6a5\/w:auto\/h:auto\/q:mauto\/f:best\/https:\/\/i1.wp.com\/www.healio.com\/~\/media\/slack-news\/fm_im\/misc\/infographics\/2026\/03_march\/pc0326shick_graphic_01_web.jpg?w=800&ssl=1&w=100&resize=100&ssl=1 100w, https:\/\/mlmjbqro95r8.i.optimole.com\/cb:bOxR.6a5\/w:auto\/h:auto\/q:mauto\/f:best\/https:\/\/i1.wp.com\/www.healio.com\/~\/media\/slack-news\/fm_im\/misc\/infographics\/2026\/03_march\/pc0326shick_graphic_01_web.jpg?w=800&ssl=1&w=150&resize=150&ssl=1 150w, https:\/\/mlmjbqro95r8.i.optimole.com\/cb:bOxR.6a5\/w:auto\/h:auto\/q:mauto\/f:best\/https:\/\/i1.wp.com\/www.healio.com\/~\/media\/slack-news\/fm_im\/misc\/infographics\/2026\/03_march\/pc0326shick_graphic_01_web.jpg?w=800&ssl=1&w=240&resize=240&ssl=1 240w, https:\/\/mlmjbqro95r8.i.optimole.com\/cb:bOxR.6a5\/w:auto\/h:auto\/q:mauto\/f:best\/https:\/\/i1.wp.com\/www.healio.com\/~\/media\/slack-news\/fm_im\/misc\/infographics\/2026\/03_march\/pc0326shick_graphic_01_web.jpg?w=800&ssl=1&w=320&resize=320&ssl=1 320w, https:\/\/mlmjbqro95r8.i.optimole.com\/cb:bOxR.6a5\/w:auto\/h:auto\/q:mauto\/f:best\/https:\/\/i1.wp.com\/www.healio.com\/~\/media\/slack-news\/fm_im\/misc\/infographics\/2026\/03_march\/pc0326shick_graphic_01_web.jpg?w=800&ssl=1&w=500&resize=500&ssl=1 500w, https:\/\/mlmjbqro95r8.i.optimole.com\/cb:bOxR.6a5\/w:auto\/h:auto\/q:mauto\/f:best\/https:\/\/i1.wp.com\/www.healio.com\/~\/media\/slack-news\/fm_im\/misc\/infographics\/2026\/03_march\/pc0326shick_graphic_01_web.jpg?w=800&ssl=1&w=640&resize=640&ssl=1 640w, https:\/\/mlmjbqro95r8.i.optimole.com\/cb:bOxR.6a5\/w:auto\/h:auto\/q:mauto\/f:best\/https:\/\/i1.wp.com\/www.healio.com\/~\/media\/slack-news\/fm_im\/misc\/infographics\/2026\/03_march\/pc0326shick_graphic_01_web.jpg?w=800&ssl=1&w=800&resize=800&ssl=1 800w, https:\/\/mlmjbqro95r8.i.optimole.com\/cb:bOxR.6a5\/w:auto\/h:auto\/q:mauto\/f:best\/https:\/\/i1.wp.com\/www.healio.com\/~\/media\/slack-news\/fm_im\/misc\/infographics\/2026\/03_march\/pc0326shick_graphic_01_web.jpg?w=800&ssl=1&w=1024&resize=1024&ssl=1 1024w, https:\/\/mlmjbqro95r8.i.optimole.com\/cb:bOxR.6a5\/w:auto\/h:auto\/q:mauto\/f:best\/https:\/\/i1.wp.com\/www.healio.com\/~\/media\/slack-news\/fm_im\/misc\/infographics\/2026\/03_march\/pc0326shick_graphic_01_web.jpg?w=800&ssl=1&w=1280&resize=1280&ssl=1 1280w, https:\/\/mlmjbqro95r8.i.optimole.com\/cb:bOxR.6a5\/w:auto\/h:auto\/q:mauto\/f:best\/https:\/\/i1.wp.com\/www.healio.com\/~\/media\/slack-news\/fm_im\/misc\/infographics\/2026\/03_march\/pc0326shick_graphic_01_web.jpg?w=800&ssl=1&w=1600&resize=1600&ssl=1 1600w\" fifu-data-src=\"https:\/\/mlmjbqro95r8.i.optimole.com\/cb:bOxR.6a5\/w:auto\/h:auto\/q:mauto\/f:best\/https:\/\/i1.wp.com\/www.healio.com\/~\/media\/slack-news\/fm_im\/misc\/infographics\/2026\/03_march\/pc0326shick_graphic_01_web.jpg?w=800&ssl=1\" alt=\"PC0326Shick_Graphic_01_WEB\" class=\"figure-img img-fluid\" width=\"800\"><figcaption class=\"figure-caption\"> <\/figcaption><\/figure>\n<p>Healio spoke with Shick to learn more about the changes, the real-world impact, what PCPs need to know and more.<\/p>\n<p> <b>Healio: What exactly were the updates to digital health guidance that FDA released on Jan. 6, and then revised on Jan. 29?<\/b> <\/p>\n<p> <b>Shick:<\/b> Just to be clear, this isn\u2019t exhaustive \u2014 these are multi-page policies.<\/p>\n<p>There were two digital health guidances that were updated Jan. 6, and that was the clinical decision support guidance and the general wellness guidance. The clinical decision support guidance was updated again on Jan. 29. These are really interesting times. I was previously a senior digital health advisor on the policy team in the Digital Health Center of Excellence at the FDA. And, typically, when guidance like these are updated, they\u2019re usually updated in a draft format. There\u2019s an opportunity for public comment. There\u2019s a very specific process. This year, they were announced at Consumer Electronics Show, which was really unique and exciting.<\/p>\n<p>So, what changed? We had <a rel=\"noopener noreferrer\" href=\"https:\/\/www.healio.com\/news\/primary-care\/20250306\/makary-vows-fda-will-uphold-gold-standard-of-trusted-science-during-senate-hearing\" id=\"rId13\" target=\"_blank\">the commissioner<\/a> on stage saying that, \u201cwe need regulatory to be working at Silicon Valley speeds.\u201d <\/p>\n<p>A significant update is that there\u2019s now an opportunity for clinical decision support software to have a single recommendation. Before, any clinical decision support that had a single recommendation was sort of default regulated. If something came across my desk when I was at FDA and the output was a single recommendation, it immediately failed the non-device criteria, which meant you needed authorization from FDA before you could bring it to market. Now it\u2019s been clarified that in scenarios where it is not clinically relevant, it is possible to have a singular recommendation. But this is much trickier than I think folks in the wellness and wearables and digital health space may realize. Let me put it this way, if any of my clients or anyone working with me is like, \u201cHey, we\u2019re trying to put a clinical decision support software out, and we don\u2019t want it to be regulated by FDA,\u201d I would say, \u201cAll right, you\u2019re going to be in a much better situation if the output of your software is providing recommendations with an \u2018s\u2019 instead of being prescriptive, because a singular recommendation still is going to require a lot of justification that no other output is clinically relevant, and it\u2019s very possible that FDA may ask you to come in for a cue submission meeting to kind of lift up the hood \u2014 show us how your system works.\u201d<\/p>\n<p>One of the things that was said is that clinical decision support software was being made artificially dumber and harder to use by health care providers because of some of these policies. So, the intent was for the policy to be updated specifically for this purpose. Another thing is a little more clarity around health care professionals\u2019 ability to independently review the basis of a recommendation. Part of clinical decision support is that it\u2019s not replacing the judgment of a health care professional; it is kind of speeding up the organization and presentation of the information that the health care professional needs to make decisions. There has also been some additional clarity around who the user is. So, something that\u2019s really important for folks to know about clinical decision support \u2014 this was already clear \u2014 is that something cannot be non-device clinical decision support unless it\u2019s intended to be used by a health care professional. If you\u2019re creating clinical decision support intended for use by a caregiver or a patient, the non-device policy isn\u2019t applicable.<\/p>\n<p>Then, there were also some changes to the general wellness policy for low-risk devices. There\u2019s a little more of a nuance that was added around wearable devices sensing information and notifications. The thing is, a lot of companies think that if they just say, \u201cwe\u2019re a wellness product,\u201d that then it\u2019s like that scene in \u201cStar Wars\u201d where Obi-Wan says, \u201cThese are not the droids you\u2019re looking for,\u201d and the stormtroopers walk away. That\u2019s what people think. But actually, you can\u2019t just say we\u2019re general wellness and FDA walks away. If you were doing things that are clearly regulated device functions, those policies may not be appropriate a lot of the time. The device software function policy makes a lot more sense.<\/p>\n<p>In a lot of ways, the roots of these policies are really the same. The biggest thing that\u2019s happened is that there are more examples in these policies to really help innovators know when their product is aligned with something that\u2019s a focus of oversight vs. something that isn\u2019t.<\/p>\n<p> <b>Healio: Is this positive or negative? What will the real-world impact be here?<\/b> <\/p>\n<p> <b>Shick:<\/b> The positive change in terms of market access here is that we\u2019ve widened the scope of software in the digital health space that\u2019s able to go to market without requiring pre-market oversight and authorization from FDA. From the point of view of an innovator who\u2019s looking to figure out product market fit, get people using a product, develop functionality with the intention of building out more robust use cases as you go, this is really exciting. There\u2019s a faster path to market from the point of view of somebody who really wants to be reimbursed for the products you are creating.<\/p>\n<p>The number of things that are clearly reimbursed has narrowed a little bit. That means if your client or if your customer is, let\u2019s say, an employer or a health plan, and you\u2019re doing a [business to business] kind of play, that\u2019s one thing. But if you were planning on payers or patients, coverage providers to be covering some of this, it\u2019s extra tricky. FDA has made clear that for products that did receive authorization for being \u201cdevice clinical decision support,\u201d that even if they are no longer \u201cdevice clinical decision support\u201d under the new policy, their authorization still holds. But from the point of view of that company rolling out future products and continuing to be covered as they are now, that\u2019s a little fuzzy. Why would a payer continue paying for them as a medical device if they\u2019re no longer requiring regulation? That\u2019s a kind of sticky thing there. So, I\u2019d say it\u2019s great for innovation, but the long-term viability of different businesses is going to require a little more creativity, a different strategy.<\/p>\n<p> <b>Healio: What do those changes mean for health care providers specifically?<\/b> <\/p>\n<p> <b>Shick:<\/b> One of the problems that we see in the digital health space is health care professionals don\u2019t necessarily know when to trust digital health products, and that doesn\u2019t matter whether it\u2019s virtual medicine, digital therapeutics, wearables-based \u2014 it\u2019s just really hard for folks to know, when is this safe and effective? Which patient population does this work for? And part of FDA device authorization, you have the intended use, just like any other medical device or drug that you may use in your practice as part of patient care. You have that authorization to look at, to understand how this is substantially equivalent or safe and effective, and you can rely on that. We\u2019re seeing different opportunities for third party organizations to be doing that sort of thing but, ultimately, if you have fewer things that are receiving oversight from FDA, it\u2019s harder to know what you can trust and not trust.<\/p>\n<p>And then, of course, health care professionals are reimbursed for the time they spend doing things, whether that\u2019s part of remote patient monitoring or various other elements, and reimbursement is very, very hard in the digital health space. But there are different opportunities for waivers and other things that much of the time are tied to whether or not the product meets the definition of a device. When you have these things in enforcement discretion, that the definition of enforcement discretion under the device software policy is specifically something for which FDA does not intend to determine whether or not it is a device, or determine whether or not it\u2019s in compliance with regulations under the Federal Food, Drug and Cosmetic Act. So, it may or may not be a device. Technically, the definition of non-device clinical decision support is that it is not a device, therefore it\u2019s just not regulated. That means all of the good manufacturing practices, all kinds of things that you would typically have in place for safety and product lifecycle management do not need to be in place.<\/p>\n<p> <b>Healio: Does this impact patients? Is there anything <\/b><b>P<\/b><b>CPs should be telling their patients about these changes?<\/b> <\/p>\n<p> <b>Shick: <\/b>I would say this definitely impacts patients from the point of view of, it\u2019s a lot easier for more folks to have things out there and be marketing it. From the point of view of clinical decision support \u2014 the way the policy is written \u2014 clinical decision support should only be facing health care professionals. And this could be a clinical decision support software function embedded within the electronic medical records.<\/p>\n<p>I\u2019ve seen clinical decision support to help people manage aesthetic procedures, like related to Botox or fillers. I\u2019ve seen clinical decision support around oncology care. Clinical decision support can affect a lot of things, and so from the point of view of a patient, non-authorized clinical decision support means that your health care professional has a tool to help them make decisions more quickly, but ultimately their clinical judgment is how the risk is managed. They are still responsible, it\u2019s just there\u2019s a little bit less oversight than there was at another point, making sure that this health care professional has everything they need, so that they don\u2019t rely on the output of this software for the basis of their decision.<\/p>\n<p>It would be great if health care professionals would communicate to patients when they are using a clinical decision support software, like, \u201cOh, hey, I looked at this. Having said that, this is within the practice of medicine.\u201d Health care professionals use all sorts of tools, it would be absurd to disclose all of these to your patients. If there was one that was maybe particularly integral to the clinical workflow and process, that could be something to disclose. That\u2019s something that really is just from a public service announcement \u2014 things that I would like patients in America to know. Also, we\u2019re now at a time where the U.S. has really adjusted oversight and enforcement in the digital health space in a way that is very clearly prioritizing innovation, in ways that, say, you wouldn\u2019t necessarily see in the EU or UK.<\/p>\n<p> <b>Healio: What is the take-home message here?<\/b> <\/p>\n<p> <b>Shick:<\/b> The first thing I would want people to get out of this is that there\u2019s more opportunity for finding product market fit and early access to customers, so long as you are aligning your marketing and your user interface with those policies. However, at the same time, you need to be extra savvy about what your business and payment or reimbursement strategy is, because that\u2019s now more challenging than it was before.<\/p>\n<p>I want folks to be excited, but cautiously optimistic. The big thing here is that folks really need to be aligning with these policies and not just taking some of the rhetoric and the promotional stuff around this \u2014 like \u201cmoving at Silicon Valley speed.\u201d Getting out of the way, being more user friendly \u2014 all this sounds great, but the policy is still the policy and you still need to align with it. I\u2019m still helping clients with allegations and compliance within these policies all the time, and it can be done. What I tell people is you can have the exact same software functionality, the exact same code, and based on how you market it and how you describe your intended use and your user interface, it could be non-device, general wellness, enforcement, discretion or fully regulated, just by changing words.<\/p>\n<h2>For more information:<\/h2>\n<p> <b>Aubrey Shick<\/b> can be reached on <a rel=\"noopener noreferrer\" href=\"https:\/\/www.linkedin.com\/in\/aubreyshick\/\" id=\"rId14\" target=\"_blank\">LinkedIn @AubreyShick<\/a>.<\/p>\n<div class=\"article__content--footer\">\n<div class=\"sources-references-disclosures\">\n<h3>Sources\/Disclosures<\/h3>\n<h2> Source: <\/h2>\n<p class=\"citation\">Healio Interviews<\/p>\n<h2>References: <\/h2>\n<div class=\"disclosures\">\n<p> <strong> Disclosures: <\/strong> Shick reports no relevant financial disclosures. <\/p>\n<\/p><\/div>\n<\/div>\n<p> <!-- Healio AI Widget --> <\/p>\n<div class=\"healio-ai-component-inline\" data-no-ads=\"true\" data-module-track-category=\"Healio AI\" data-module-track-action=\"Click\" data-module-track-label=\"Access Healio Ai from component - News_AI Component - In-Content (all devices)\">\n<div class=\"healio-ai-content\"> <img data-opt-id=758893364  fetchpriority=\"high\" decoding=\"async\" src=\"data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/ywAAAAAAQABAAACAUwAOw==\" fifu-lazy=\"1\" fifu-data-sizes=\"auto\" fifu-data-srcset=\"https:\/\/m3.healio.com\/~\/media\/images\/healio-ai\/healio-ai_logo.svg?w=75&resize=75&ssl=1 75w, https:\/\/m3.healio.com\/~\/media\/images\/healio-ai\/healio-ai_logo.svg?w=100&resize=100&ssl=1 100w, https:\/\/m3.healio.com\/~\/media\/images\/healio-ai\/healio-ai_logo.svg?w=150&resize=150&ssl=1 150w, https:\/\/m3.healio.com\/~\/media\/images\/healio-ai\/healio-ai_logo.svg?w=240&resize=240&ssl=1 240w, https:\/\/m3.healio.com\/~\/media\/images\/healio-ai\/healio-ai_logo.svg?w=320&resize=320&ssl=1 320w, https:\/\/m3.healio.com\/~\/media\/images\/healio-ai\/healio-ai_logo.svg?w=500&resize=500&ssl=1 500w, https:\/\/m3.healio.com\/~\/media\/images\/healio-ai\/healio-ai_logo.svg?w=640&resize=640&ssl=1 640w, https:\/\/m3.healio.com\/~\/media\/images\/healio-ai\/healio-ai_logo.svg?w=800&resize=800&ssl=1 800w, https:\/\/m3.healio.com\/~\/media\/images\/healio-ai\/healio-ai_logo.svg?w=1024&resize=1024&ssl=1 1024w, https:\/\/m3.healio.com\/~\/media\/images\/healio-ai\/healio-ai_logo.svg?w=1280&resize=1280&ssl=1 1280w, https:\/\/m3.healio.com\/~\/media\/images\/healio-ai\/healio-ai_logo.svg?w=1600&resize=1600&ssl=1 1600w\" fifu-data-src=\"https:\/\/m3.healio.com\/~\/media\/images\/healio-ai\/healio-ai_logo.svg\" alt=\"Healio AI\" class=\"healio-ai-logo\"> <\/p>\n<p><strong>Ask a clinical question<\/strong> and tap into <strong>Healio AI&#8217;s knowledge<\/strong> base.<\/p>\n<ul>\n<li>PubMed, enrolling\/recruiting trials, guidelines<\/li>\n<li>Clinical Guidance, Healio CME, FDA news<\/li>\n<li>Healio&#8217;s exclusive daily news coverage of clinical data<\/li>\n<\/ul>\n<p> <button class=\"healio-ai-button\">Learn more<\/button> <\/div>\n<\/div>\n<div class=\"row\">\n<div class=\"col\">\n<div class=\"chips-group\">\n<p>Read more about<\/p>\n<\/p><\/div>\n<\/p><\/div>\n<\/div>\n<div class=\"email-alert-button-wrapper d-none\" data-component=\"EmailTopicAlert\" data-module=\"Subspecialty Email Topic Alerts Top\" data-manage-email-link=\"\/footer\/account-information\/my-account\/email-subscriptions-and-alerts#emailAlerts\">\n<div class=\"email-alert-button d-none\" data-topic-button=\"not-subscribed\">\n<p> <span data-module-track-action=\"Email Alerts TOP_Click_Healio News Article\" data-module-track-label=\"Email Alerts TOP_Healio News Article\"> <i class=\"fas fa-plus-circle\"><\/i> Add topic to email alerts <\/span> <\/p>\n<div class=\"email-alert-inner collapse u4d5c8cd2d9164cf9a829bee5c0694d71\">\n<div class=\"email-alert-dialogue\">\n<p> Receive an email when new articles are posted on <span data-content=\"topic-title\"><\/span> <\/p>\n<div class=\"d-none\" data-sign-up-type=\"unknown\"> Please provide your email address to receive an email when new articles are posted on <span data-content=\"topic-title\"><\/span>. <\/div>\n<\/p><\/div>\n<p> &lt;button type=&quot;button&quot; class=&quot;btn btn-primary&quot; data-loading-text=&quot;Loading <i class='fa fa-spinner fa-spin'><\/i>&#8221; data-action=&#8221;subscribe&#8221;&gt; Subscribe <\/button> <\/div>\n<\/p><\/div>\n<div class=\"email-alert-button d-none\" data-topic-button=\"subscribed\">\n<p> <i class=\"fas fa-check-circle\"><\/i> <span>Added to email alerts<\/span> <\/p>\n<\/p><\/div>\n<div class=\"d-none\" data-topic-modal=\"failed\"> <strong>We were unable to process your request. Please try again later. If you continue to have this issue please contact <a href=\"mailto:customerservice@slackinc.com\">customerservice@slackinc.com<\/a>.<\/strong> <\/p>\n<p><button data-dismiss=\"modal\" class=\"btn btn-primary btn-lg btn-block\">Back to Healio<\/button><\/p>\n<\/div>\n<\/div><\/div>\n<p><strong><a href=\"https:\/\/blockads.fivefilters.org\"> <\/a><\/strong> <a href=\"https:\/\/blockads.fivefilters.org\/acceptable.html\"> <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>&#8230; year, they were announced at <span class=\"match\">Consumer Electronics Show<\/span>, which was really unique and &#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"fifu_image_url":"","fifu_image_alt":"","footnotes":""},"categories":[1],"tags":[],"class_list":["post-137945","post","type-post","status-publish","format-standard","hentry","category-news","wpcat-1-id"],"_links":{"self":[{"href":"https:\/\/new7.shop\/zerocostfreehost\/index.php\/wp-json\/wp\/v2\/posts\/137945","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/new7.shop\/zerocostfreehost\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/new7.shop\/zerocostfreehost\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/new7.shop\/zerocostfreehost\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/new7.shop\/zerocostfreehost\/index.php\/wp-json\/wp\/v2\/comments?post=137945"}],"version-history":[{"count":0,"href":"https:\/\/new7.shop\/zerocostfreehost\/index.php\/wp-json\/wp\/v2\/posts\/137945\/revisions"}],"wp:attachment":[{"href":"https:\/\/new7.shop\/zerocostfreehost\/index.php\/wp-json\/wp\/v2\/media?parent=137945"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/new7.shop\/zerocostfreehost\/index.php\/wp-json\/wp\/v2\/categories?post=137945"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/new7.shop\/zerocostfreehost\/index.php\/wp-json\/wp\/v2\/tags?post=137945"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}